Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn’s Disease

A subset of patients with Crohn’s disease (CD) do not respond to ustekinumab at the standard dose of 90 mg every 8 weeks. Little is known about the efficacy of shortening the interval between doses. We performed a retrospective study to determine the effectiveness of ustekinumab dose interval shorte...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical gastroenterology and hepatology 2021-01, Vol.19 (1), p.104-110
Hauptverfasser:	Ollech, Jacob E., Normatov, Inessa, Peleg, Noam, Wang, Jingzhou, Patel, Shivani A., Rai, Victoria, Yi, Yangtian, Singer, Jorie, Dalal, Sushila R., Sakuraba, Atsushi, Cohen, Russell D., Rubin, David T., Pekow, Joel
Format:	Artikel
Sprache:	eng
Schlagworte:	C-Reactive Protein - metabolism Crohn Disease - drug therapy Drug Humans IBD Inflammatory Bowel Diseases Interleukin Agonist Leukocyte L1 Antigen Complex Remission Induction Retrospective Studies Severity of Illness Index Ustekinumab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!